KOBV Portal

Hits per page

hits 1 - 10 | 366 hits

Sorting

Online Resource

Proceedings of the Frontiers of Retrovirology Conference 2016

Zurnic, Irena ; Hütter, Sylvia ; Lehmann, Ute ; [et al.]

Springer Science and Business Media LLC ; 2016

In: Retrovirology Vol. 13, No. S1 ( 2016-9)

add to watchlist on the watchlist

Details

In: Retrovirology, Springer Science and Business Media LLC, Vol. 13, No. S1 ( 2016-9)

Type of Medium: Online Resource

ISSN: 1742-4690

URL: Article

DOI: 10.1186/s12977-016-0294-5

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2016

detail.hit.zdb_id: 2142602-8

SSG: 12

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn’s Disease using Real-World Data

Pillai, Nadia ; Lupatsch, Judith E ; Dusheiko, Mark ; [et al.]

Oxford University Press (OUP) ; 2020

In: Journal of Crohn's and Colitis Vol. 14, No. 4 ( 2020-05-21), p. 490-500

add to watchlist on the watchlist

Details

In: Journal of Crohn's and Colitis, Oxford University Press (OUP), Vol. 14, No. 4 ( 2020-05-21), p. 490-500

Abstract: We evaluated the cost-effectiveness of early [≤2 years after diagnosis] compared with late or no biologic initiation [starting biologics & gt;2 years after diagnosis or no biologic use] for adults with Crohn’s disease in Switzerland. Methods We developed a Markov cohort model over the patient’s lifetime, from the health system and societal perspectives. Transition probabilities, quality of life, and costs were estimated using real-world data. Propensity score matching was used to ensure comparability between patients in the early [intervention] and late/no [comparator] biologic initiation strategies. The incremental cost-effectiveness ratio [ICER] per quality-adjusted life year [QALY] gained is reported in Swiss francs [CHF]. Sensitivity and scenario analyses were performed. Results Total costs and QALYs were higher for the intervention [CHF384 607; 16.84 QALYs] compared with the comparator [CHF340 800; 16.75 QALYs] strategy, resulting in high ICERs [health system: CHF887 450 per QALY; societal: CHF449 130 per QALY]. In probabilistic sensitivity analysis, assuming a threshold of CHF100 000 per QALY, the probability that the intervention strategy was cost-effective was 0.1 and 0.25 from the health system and societal perspectives, respectively. In addition, ICERs improved when we assumed a 30% reduction in biologic prices [health system: CHF134 502 per QALY; societal: intervention dominant] . Conclusions Early biologic use was not cost-effective, considering a threshold of CHF100 000 per QALY compared with late/no biologic use. However, early identification of patients likely to need biologics and future drug price reductions through increased availability of biosimilars may improve the cost-effectiveness of an early treatment approach.

Type of Medium: Online Resource

ISSN: 1873-9946 , 1876-4479

URL: Article

DOI: 10.1093/ecco-jcc/jjz169

Language: English

Publisher: Oxford University Press (OUP)

Publication Date: 2020

detail.hit.zdb_id: 2389631-0

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study

Biedermann, Luc ; Renz, Laura ; Fournier, Nicolas ; [et al.]

SAGE Publications ; 2019

In: Therapeutic Advances in Gastroenterology Vol. 12 ( 2019-01), p. 175628481986514-

add to watchlist on the watchlist

Details

In: Therapeutic Advances in Gastroenterology, SAGE Publications, Vol. 12 ( 2019-01), p. 175628481986514-

Abstract: The knowledge about risk factors for the onset of uveitis manifestations in patients with inflammatory bowel disease (IBD) is still limited. Here, we aimed to provide an overview of the clinical factors associated with the onset of uveitis in the Swiss IBD Cohort Study (SIBDCS). Methods: We included epidemiological and clinical data from 1840 patients with Crohn’s disease (CD) and 1426 patients with ulcerative colitis (UC) followed up in the SIBDCS between 2006 and 2018. Associations between disease characteristics and uveitis were assessed in univariate and multivariate analyses. Results: Overall, we identified 285 patients with uveitis. Uveitis was more frequent in patients with CD (11.1%; 205 of 1635) than UC (5.6%; 80 of 1346; odds ratio 2.11, p 〈 0.001). The occurrence of uveitis manifestations in patients with UC and CD was significantly associated with the onset of other extraintestinal manifestations, also in multivariate analyses. The onset of uveitis was associated with the hallmark features of severe disease in both CD and UC, including a higher clinical disease activity index and the use of immunomodulators or calcineurin inhibitors. In CD, uveitis was more frequent in females and showed a positive correlation with a positive family history of IBD. Conclusions: Our data demonstrate that uveitis in IBD occurs more often in CD as well as in women and is associated with a more severe disease course. This might guide physicians’ awareness in at-risk patients to the presence of uveitis extraintestinal manifestations and help to improve patient care.

Type of Medium: Online Resource

ISSN: 1756-2848 , 1756-2848

URL: Article

DOI: 10.1177/1756284819865142

Language: English

Publisher: SAGE Publications

Publication Date: 2019

detail.hit.zdb_id: 2440710-0

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis

Siebenhüner, Alexander R. ; Rossel, Jean-Benoît ; Schreiner, Philipp ; [et al.]

SAGE Publications ; 2021

In: Therapeutic Advances in Gastroenterology Vol. 14 ( 2021-01), p. 175628482110337-

add to watchlist on the watchlist

Details

In: Therapeutic Advances in Gastroenterology, SAGE Publications, Vol. 14 ( 2021-01), p. 175628482110337-

Abstract: Anxiety and depression are prevalent in patients with inflammatory bowel diseases (IBD), especially during IBD flares. IBD therapies can profoundly affect the mood of patients with IBD. We aimed to determine the long-term impact of anti-tumor necrosis factor (anti-TNF) and immunomodulators (IM) on anxiety and depressive symptoms in IBD patients. Methods: We compared three treatment groups with IM only (group A), anti-TNF ± IM (group B) and no such therapy (group C). Patients completed the hospital anxiety and depression scale (HADS) at 1 year, 3 years, and 5 years after start of treatment. Results: In total, 581 patients with IBD (42.9% Crohn’s disease, 57.1% ulcerative colitis/IBD unclassified) participated in this study. Effects of treatment were analyzed in a mixed effects model, with and without correction for confounders. Compared with group C, group B showed a significant treatment-related improvement in both anxiety and depressive symptoms within the first 2.5 years and also thereafter. Group A showed a significant long-term improvement of anxiety and both short-term and long-term improvement in depressive symptoms. The significance of these results was maintained after correction for confounders, including corticosteroid treatment. Additionally, both groups A and B showed a significant decrease in disease activity in the first 2.5 years after start of treatment and also thereafter. Anti-TNF and IM treatment were associated with a similarly significant decrease in anxiety and depressive symptoms over an observation period of up to 5 years. Conclusion: Besides a clear benefit for disease activity, anti-TNF and IM apparently improve the mood of patients with IBD.

Type of Medium: Online Resource

ISSN: 1756-2848 , 1756-2848

URL: Article

DOI: 10.1177/17562848211033763

Language: English

Publisher: SAGE Publications

Publication Date: 2021

detail.hit.zdb_id: 2440710-0

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management

Ledergerber, Martina ; Lang, Brian M. ; Heinrich, Henriette ; [et al.]

Springer Science and Business Media LLC ; 2021

In: BMC Gastroenterology Vol. 21, No. 1 ( 2021-02-05)

add to watchlist on the watchlist

Details

In: BMC Gastroenterology, Springer Science and Business Media LLC, Vol. 21, No. 1 ( 2021-02-05)

Abstract: Abdominal pain is a frequent symptom in patients with inflammatory bowel disease (IBD) including Crohn’s disease (CD) and ulcerative colitis (UC). Pain can result from ongoing inflammation or functional disorders imitating irritable bowel syndrome (IBS). Several single-nucleotide polymorphisms (SNPs) have been associated with IBS. However, the impact of IBS genetics on the clinical course of IBD, especially pain levels of patients remains unclear. Methods Data of 857 UC and 1206 CD patients from the Swiss IBD Cohort Study were analysed. We tested the association of the maximum of the abdominal pain item of disease activity indices in UC and CD over the study period with 16 IBS-associated SNPs, using multivariate ANOVA models. Results In UC patients, the SNPs rs1042713 (located on the ADRB2 gene) and rs4663866 (close to the HES6 gene) were associated with higher abdominal pain levels ( P = 0.044; P = 0.037, respectively). Abdominal pain was not associated with any markers of patient management in a model adjusted for confounders. In CD patients, higher levels of abdominal pain correlated with the number of physician contacts ( P 〈 10 –15 ), examinations ( P 〈 10 –12 ), medical therapies ( P = 0.023) and weeks of hospitalisation ( P = 0.0013) in a multivariate model. Conclusions We detected an association between maximal abdominal pain in UC patients and two IBS-associated SNPs. Abdominal pain levels had a pronounced impact on diagnostic and therapeutic procedures in CD but not in UC patients.

Type of Medium: Online Resource

ISSN: 1471-230X

URL: Article

DOI: 10.1186/s12876-021-01622-x

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2021

detail.hit.zdb_id: 2041351-8

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Mass spectrometric comparison of N-glycan profiles from Caenorhabditis elegans mutant embryos

Geyer, Hildegard ; Schmidt, Martin ; Müller, Matthias ; [et al.]

Springer Science and Business Media LLC ; 2012

In: Glycoconjugate Journal Vol. 29, No. 2-3 ( 2012-4), p. 135-145

add to watchlist on the watchlist

Details

In: Glycoconjugate Journal, Springer Science and Business Media LLC, Vol. 29, No. 2-3 ( 2012-4), p. 135-145

Type of Medium: Online Resource

ISSN: 0282-0080 , 1573-4986

URL: Article

DOI: 10.1007/s10719-012-9371-8

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2012

detail.hit.zdb_id: 1483682-8

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals

Pittet, Valérie E.H. ; Maillard, Michel H. ; Simonson, Thomas ; [et al.]

Elsevier BV ; 2019

In: Clinical Gastroenterology and Hepatology Vol. 17, No. 10 ( 2019-09), p. 2050-2059.e1

add to watchlist on the watchlist

Details

In: Clinical Gastroenterology and Hepatology, Elsevier BV, Vol. 17, No. 10 ( 2019-09), p. 2050-2059.e1

Type of Medium: Online Resource

ISSN: 1542-3565

URL: Article

DOI: 10.1016/j.cgh.2018.11.029

Language: English

Publisher: Elsevier BV

Publication Date: 2019

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Plasma proteome profiles treatment efficacy of incretin dual agonism in diet‐induced obese female and male mice

Sachs, Stephan ; Niu, Lili ; Geyer, Philipp ; [et al.]

Wiley ; 2021

In: Diabetes, Obesity and Metabolism Vol. 23, No. 1 ( 2021-01), p. 195-207

add to watchlist on the watchlist

Details

In: Diabetes, Obesity and Metabolism, Wiley, Vol. 23, No. 1 ( 2021-01), p. 195-207

Abstract: Unimolecular peptides targeting the receptors for glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) (GLP‐1/GIP co‐agonist) have been shown to outperform each single peptide in the treatment of obesity and cardiometabolic disease in preclinical and clinical trials. By combining physiological treatment endpoints with plasma proteomic profiling (PPP), we aimed to identify biomarkers to advance non‐invasive metabolic monitoring of compound treatment success and exploration of ulterior treatment effects on an individual basis. Materials and methods We performed metabolic phenotyping along with PPP in body weight‐matched male and female diet‐induced obese (DIO) mice treated for 21 days with phosphate‐buffered saline, single GIP and GLP‐1 mono‐agonists, or a GLP‐1/GIP co‐agonist. Results GLP‐1R/GIPR co‐agonism improved obesity, glucose intolerance, non‐alcoholic fatty liver disease (NAFLD) and dyslipidaemia with superior efficacy in both male and female mice compared with mono‐agonist treatments. PPP revealed broader changes of plasma proteins after GLP‐1/GIP co‐agonist compared with mono‐agonist treatments in both sexes, including established and potential novel biomarkers for systemic inflammation, NAFLD and atherosclerosis. Subtle sex‐specific differences have been observed in metabolic phenotyping and PPP. Conclusions We herein show that a recently developed unimolecular GLP‐1/GIP co‐agonist is more efficient in improving metabolic disease than either mono‐agonist in both sexes. PPP led to the identification of a sex‐independent protein panel with the potential to monitor non‐invasively the treatment efficacies on metabolic function of this clinically advancing GLP‐1/GIP co‐agonist.

Type of Medium: Online Resource

ISSN: 1462-8902 , 1463-1326

URL: Issue

URL: Article

DOI: 10.1111/dom.v23.1

DOI: 10.1111/dom.14215

Language: English

Publisher: Wiley

Publication Date: 2021

detail.hit.zdb_id: 2004918-3

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Table_7.xlsx

Baßler, Kevin ; Fujii, Wataru ; Kapellos, Theodore S. ; [et al.]

Frontiers Media SA ; 2022

In: Frontiers in Immunology Vol. 13 ( 2022-7-28)

add to watchlist on the watchlist

Details

In: Frontiers in Immunology, Frontiers Media SA, Vol. 13 ( 2022-7-28)

Abstract: Despite its high prevalence, the cellular and molecular mechanisms of chronic obstructive pulmonary disease (COPD) are far from being understood. Here, we determine disease-related changes in cellular and molecular compositions within the alveolar space and peripheral blood of a cohort of COPD patients and controls. Myeloid cells were the largest cellular compartment in the alveolar space with invading monocytes and proliferating macrophages elevated in COPD. Modeling cell-to-cell communication, signaling pathway usage, and transcription factor binding predicts TGF-β1 to be a major upstream regulator of transcriptional changes in alveolar macrophages of COPD patients. Functionally, macrophages in COPD showed reduced antigen presentation capacity, accumulation of cholesteryl ester, reduced cellular chemotaxis, and mitochondrial dysfunction, reminiscent of impaired immune activation.

Type of Medium: Online Resource

ISSN: 1664-3224

URL: Article

DOI: 10.3389/fimmu.2022.917232

DOI: 10.3389/fimmu.2022.917232.s001

DOI: 10.3389/fimmu.2022.917232.s002

DOI: 10.3389/fimmu.2022.917232.s003

DOI: 10.3389/fimmu.2022.917232.s004

DOI: 10.3389/fimmu.2022.917232.s005

DOI: 10.3389/fimmu.2022.917232.s006

DOI: 10.3389/fimmu.2022.917232.s007

DOI: 10.3389/fimmu.2022.917232.s008

DOI: 10.3389/fimmu.2022.917232.s009

DOI: 10.3389/fimmu.2022.917232.s010

DOI: 10.3389/fimmu.2022.917232.s011

DOI: 10.3389/fimmu.2022.917232.s012

DOI: 10.3389/fimmu.2022.917232.s013

DOI: 10.3389/fimmu.2022.917232.s014

Language: Unknown

Publisher: Frontiers Media SA

Publication Date: 2022

detail.hit.zdb_id: 2606827-8

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Publisher Correction: Rational discovery of molecular glue degraders via scalable chemical profiling

Mayor-Ruiz, Cristina ; Bauer, Sophie ; Brand, Matthias ; [et al.]

Springer Science and Business Media LLC ; 2021

In: Nature Chemical Biology Vol. 17, No. 3 ( 2021-03), p. 361-361

add to watchlist on the watchlist

Details

In: Nature Chemical Biology, Springer Science and Business Media LLC, Vol. 17, No. 3 ( 2021-03), p. 361-361

Type of Medium: Online Resource

ISSN: 1552-4450 , 1552-4469

URL: Article

DOI: 10.1038/s41589-021-00735-4

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2021

detail.hit.zdb_id: 2190276-8

SSG: 12

SSG: 15,3

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

hits 1 - 10 | 366 hits

Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.

Kooperativer Bibliotheksverbund

Berlin Brandenburg